James Kasinger Sells 2,800 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 2,800 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $147,840.00. Following the sale, the general counsel owned 87,815 shares in the company, valued at approximately $4,636,632. The trade was a 3.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CRISPR Therapeutics Stock Down 0.2%

Shares of NASDAQ CRSP opened at $48.75 on Friday. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The firm has a market cap of $4.68 billion, a P/E ratio of -7.48 and a beta of 1.72. The company has a 50 day moving average of $54.10 and a 200 day moving average of $57.24.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. During the same period last year, the company posted ($1.01) earnings per share. The business’s revenue was down 97.8% compared to the same quarter last year. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its position in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after acquiring an additional 735,084 shares during the period. Orbis Allan Gray Ltd boosted its stake in shares of CRISPR Therapeutics by 19.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock worth $312,026,000 after acquiring an additional 968,060 shares during the last quarter. Capital International Investors grew its position in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after acquiring an additional 243,487 shares during the period. State Street Corp increased its stake in shares of CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after purchasing an additional 859,334 shares in the last quarter. Finally, GSK plc purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth $168,890,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRSP has been the topic of several recent analyst reports. Citizens Jmp dropped their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. Needham & Company LLC boosted their target price on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Chardan Capital upped their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. TD Cowen raised their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a report on Friday, February 13th. Finally, Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $64.24.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: management reported $116M in FY‑25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer‑term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near‑term EPS adjustments (slightly less negative for FY‑2026/FY‑2027), a modest constructive signal for near‑term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most‑searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short‑interest data appears noisy: recent feeds show inconsistent/zero short‑interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell‑off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near‑term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi‑percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.